Published in final edited form as:

Palliat Support Care. 2019 April ; 17(2): 221–226. doi:10.1017/S1478951518000135.

A Qualitative Examination of the Factors related to the Development and Maintenance of Insomnia in Cancer Survivors

Sheila N. Garland¹, Frances K. Barg², Brigid Cakouros², Philip Gehrman³, Katherine N. DuHamel⁴, Jun. J. Mao⁵

¹Department of Psychology, Memorial University of Newfoundland, St. John's, NL, Canada

²Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, PA

³Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

⁴Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY

⁵The Bendheim Center for Integrative Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

Abstract

Objective—Insomnia is under recognized and inadequately managed with close to 60% of cancer survivors experiencing insomnia at some point in the treatment trajectory. The objective of this study was to further understand predisposing, precipitating and perpetuating factors in the development and maintenance of insomnia in cancer survivors.

Methods—A heterogeneous sample of 63 patients who had completed active treatment were recruited. Participants were required to have a score >7 on the Insomnia Severity Index and meet the diagnostic criteria for insomnia disorder. Open-ended, semi-structured interviews were conducted to elicit participants' experiences with sleep problems. An a priori set of codes and a set of codes that emerged from the data were used to analyze the data.

Results—The mean age of the sample was 60.5 years, with 30% identifying as non-white and 59% reporting their sex as female. The cancer types represented was heterogeneous with the two most common being breast (30%) and prostate (21%). Participants described an inherited risk for insomnia, anxious temperament, and insufficient ability to relax as predisposing factors. Respondents were split as to whether they classified their cancer diagnosis as the precipitating factor for their insomnia. Participants reported several behaviors that are known to perpetuate problems with sleep including napping, using back-lit electronics before bed, and poor sleep hygiene. One of the most prominent themes identified was the use of sleeping medications. Participants reported that they were reluctant to take medication but felt that it was the only option to treat their insomnia and that it was encouraged by their doctors.

Significance of Results—Insomnia is a prevalent, but highly treatable, disorder in cancer survivors. Patients and provider education is needed to change individual and organizational behaviors that contribute to the development and maintenance of insomnia and increase access to evidence-based nonpharmacological interventions.

Keywords

insomnia disorder; cancer; qualitative research; cognitive-behavioral therapy

Insomnia in cancer patients is under recognized and inadequately managed with close to 60% of people treated for cancer experiencing insomnia (Savard, Ivers, Villa, Caplette-Gingras, & Morin, 2011). Insomnia is a disorder characterized by a dissatisfaction with sleep quality or difficulty falling asleep, staying asleep, or waking up too early at least three times per week for the past three months (American Psychiatric Association, 2013). Insomnia in cancer patients can have significant consequences including, but not limited to, an increased risk of infections (Ruel, Savard, & Ivers, 2015), decreased overall quality of life (Lis, Gupta, & Grutsch, 2008), higher risk of (and poorer recovery from) depression and anxiety (Irwin, 2013), and greater severity of other cancer-related symptoms (Stepanski et al., 2009).

The behavioral model of insomnia, also known as Spielman's 3P model aims to explain interactions among predisposing, precipitating and perpetuating factors in the development of insomnia (See Figure 1). Predisposing and precipitating factors explain insomnia development, whereas perpetuating factors explain the mechanisms by which insomnia can become chronic. Predisposing factors represent the underlying vulnerability to develop insomnia and comprise biological features such as genetic predisposition, age and sex and psychological traits such as the tendency to worry and/or ruminate (Spielman, Caruso, & Glovinsky, 1987). A predisposition to sleep disturbance, however, requires a sufficiently stressful precipitant, or combination of precipitants, before it is expressed. Precipitating factors are thought to be acute occurrences of a stress-related trigger. Diseases that disrupt homeostasis, including cancer, can be broadly thought of as both physical and psychological stressors (Drake & Roth, 2006).

Perpetuating factors refer to the behaviors that an individual engages in while attempting to manage a sleep difficulty. Examples include: going to bed earlier, "trying" harder to sleep, napping during the day, engaging in activities other than sleep while in bed, worrying about the effects of poor sleep, and taking sleeping medication. These behaviors may seem to make sense for an individual who is struggling to sleep but they actually contribute to the development of "conditioned insomnia".

Insomnia can become 'conditioned' when sleep related stimuli are repeatedly paired with wakefulness, producing a classically conditioned cognitive and somatic arousal response, which can then become a perpetuating factor. Individuals develop sleep related anxiety and will often worry about not being able to sleep earlier in the day or evening and the potential consequences the next day if they don't. This sleep anxiety and effort serves to make it even more unlikely that they will sleep and reinforces their feelings of powerlessness and frustration, creating a repetitive nightly pattern. Thus, the 3P model provides a solid

explanation for how acute insomnia can develop into chronic insomnia (Perlis, Shaw, Cano, & Espie, 2011).

Objective

The objective of this study was to further understand predisposing, precipitating and perpetuating factors in the development and maintenance of insomnia in cancer survivors. This information will help to refine our treatment methods for this population.

Methods

Participants

We recruited a sample of 63 patients who consented to enroll in a comparative effectiveness trial of Cognitive Behavioral Therapy for Insomnia (CBT-I) vs. acupuncture [Clinical trial registration: NCT02356575] (Garland, Gehrman, Barg, Xie, & Mao, 2016). Qualitative interviews took place prior to participants' randomization into one of the two treatment arms. We included all interested English-speaking individuals over the age of 18 years with a cancer diagnosis with no restrictions placed on tumor location or stage. Because many active treatments are known to have deleterious, but temporary, effects on sleep (e.g. corticosteroid medications), participants were required to have completed active treatment (surgery, chemotherapy, and radiotherapy) at least one month prior to study initiation. Patients on continued hormone treatment or maintenance targeted therapies were not excluded. Participants were required to have a score >7 on the Insomnia Severity Index and meet the criteria for insomnia disorder as defined by the Diagnostic and Statistical Manual of Mental disorders, 5th Edition (DSM-5) as determined by clinical interview. Patients were screened for the following exclusionary conditions: the presence of another sleep disorder not adequately treated, previous experience with CBT or acupuncture for insomnia, the presence of another psychological disorder not in remission or adequately treated, and employment in a job requiring shift work that would impair the ability to establish a regular sleep schedule.

Procedure

Open-ended, semi-structured interviews were conducted to elicit participants' experiences with sleep problems during and after their cancer treatment. A copy of the interview guide is included in Appendix A. A trained research assistant (RA) conducted the interviews, with support from personnel at the Mixed Methods Research Lab (MMRL). At the completion of each interview, the RA dictated field notes about their impressions during the interview as well as interview circumstances that may have affected the data that were recorded. Interviews were audio recorded, transcribed, de-identified and entered into an NVivo 10 database for coding and analysis.

Analysis

We used an integrated approach to the analysis of the data (Curry, Nembhard, & Bradley, 2009). Two forms of codes were used: an a priori set of codes derived from the key ideas we are seeking to understand (e.g. predisposing, precipitating, and perpetuating factors) and

a set of codes that emerged from the data themselves. A data dictionary was developed that included all codes, their definitions, and decision rules for applying the code. Every fourth transcript was double coded and we used the interrater reliability function in NVivo to ascertain agreement between coders. Any discrepancies were resolved by consensus.

Results

Participant Characteristics

Demographics and clinical characteristics of the sample are presented in Table 1.

Predisposing Factors

Participants described a family predisposition to insomnia, anxious temperaments, and insufficient ability to relax as factors that predisposed them to insomnia. Individuals who noticed similar behavior in other family members suggested that insomnia might have been passed on to them from their parents. Attributions ranged from genetic explanations to biological tendencies and behavioral factors.

“I finally had the realization when we took a family vacation and all three of my family members – everybody else was sleeping and all three of my family members were up in the middle of the night, as well as my mom. So our whole family is like up and around, walking around in the middle of the night.” (Female, 54 yrs, lymphoma)

Others cited a natural tendency toward anxiety since childhood. This anxious temperament was identified as something present throughout the day that also interfered with sleep at night.

“I’m a worrywart. I’ve always worried about my parents – if it was my parents, or my siblings – or then when I got married, my husband traveled a lot and worrying about his safety with his travels, and again, the children.” (Female, 68 yrs, myelofibrosis)

Several participants discussed the experience of not knowing how to relax or being “unable to shut off their thoughts” at night. The content of this thought consisted of activities such as ruminating about past events, planning and thinking about future activities, and random, unrelated images. While this tendency to have an active mind at night can predispose one to develop insomnia is also works as a perpetuating factor because the bed can eventually be conditioned to elicit this mental processing after repeated pairings.

“One of the things I noted is I can’t shut down my thoughts. My thoughts just race through the night. So, I do a lot of thinking and processing of issues and replaying events, and my mind is too alert. It just reprocesses everything that’s happened, either that day, two weeks ago, the day before. What I could’ve done, should’ve done.” (Female, 52 yrs, ovarian)

Precipitating Factors

Respondents were split as to whether they classified their cancer diagnosis as the precipitating factor for their insomnia or whether it made a pre-existing problem with

sleep worse. For those that reported that cancer was the trigger for insomnia, the difficulty sleeping was mainly triggered by the emotional impact of the diagnosis, the impact of hospitalization, or treatments such as chemotherapy or radiation.

“I would probably say right around the time – well, after the diagnosis. But, you know, your mind is racing at that point in time thinking about what could be and always thinking about anticipating the worst and so forth. So that was fine. That, to me, appeared to be very normal. But then, after going through the chemo and radiation and still finding that, okay, we’re almost a year out and there’s still this inability to go to sleep or to resort back to what the sleeping or behavior patterns were prior to. So that’s when I took notice of my sleep patterns and I did talk to my primary care physician.” (Female, 45 yrs, breast)

Several participants acknowledged that they had difficulty sleeping prior to their cancer diagnosis but that impact of stress related to the cancer diagnosis or the effects of cancer treatments made a pre-existing problem worse.

“Well, I think the factor is the therapy I’m getting, the hormone deprivation. Androgen depletion therapy is – I mean, that clearly is what initiated a chronic problem, as opposed to an acute situation that may have occurred every once in a great while. I’m sure aging is probably part of it, too.” (Male, 64 yrs, prostate)

Other people were not able to identify a precipitating factor related to the development of their insomnia. The lack of a specific trigger left them to speculate that their insomnia might be related to biological or aging factors.

“My stress level is – I have nothing really to worry about. It’s – I don’t have to worry about a job. I don’t know what could cause it. Maybe there’s something internal that I don’t know that’s going on. I don’t know if it can be medical.” (Male, 58 yrs, leukemia)

Perpetuating Factors

Perpetuating factors refer to the behaviors that an individual engages in while attempting to manage their sleep difficulty, which in turn actually contribute to the persistence of insomnia. In describing their experience, participants reported several behaviors that are known to interfere with sleep. These included taking naps during the day, using backlit electronics before bed, use of sleeping medications, and poor sleep hygiene. For those people who napped during the day, there was a recognition that it affected their ability to sleep at night but they felt like they did not have better options to manage their levels of daytime fatigue.

“And then the other thing is I take a nap every day. I think I told you. Most days I do. And sometimes I feel as though when I don’t take a nap I sleep better at night sometimes.” (Male, 83 yrs, prostate)

Some participants were aware of the connection between backlit devices and sleep disturbance and were actively trying to reduce their pre-bed screen time, acknowledging the negative impact of the device on sleep.

“Usually I sort of play something on my phone to sort of make myself sleepy since I get in bed and then you’re wide awake. It’s the opposite of my husband who hits the bed and is snoring. So sometimes when I do that, I get engaged in what I’m doing on the phone and then I end up staying up even later because – I don’t know, then I’m not tired and all of a sudden – eventually get tired and fall asleep. And that’s certainly not good because I get up about quarter to five, 4:30 – 5:00, every day.” (Female, 57 yrs, breast)

One of the most pervasive perpetuating behaviors reported by participants was the use of sleeping medication, both prescribed and over the counter. Many people reported having tried several medications or having to switch or alternate between different medications to maintain an effect. Participants also noted that they would develop tolerance for the sleep medications after a period of time and even when effective, the medication was often only helpful in the short term with decreased effectiveness as time passed.

“The Ativan usually – I’ll sleep pretty well when I take that as long as I don’t take it multiple nights. I find that if I take it one or two, maybe three nights in a row, that usually is pretty good. But if I’ve been taking it more than that, I find that the impact is lessened. It’s like probably a tolerance or something. The other one that I can’t think of the name of – starts with an M – I can see the bottle in my medicine cabinet in the bathroom and I can’t think of the name – it’s really gonna bug me, but that one does help. It does usually help.” (Male, 45 yrs, pancreatic)

Many spoke about a reluctance to take medication but felt like they did not have other options available.

“I just could not sleep until I started taking Klonopin and some other crazy drug. And they knocked me out, but – Klonopin and Trazodone. And I tried them individually, and they still wouldn’t knock me out. And I remember my primary care physician – Trazodone were like horse pills. I think they were 150 mg or something. And I talked to my primary care physician, she said, [Participant’s Name], that pill will knock out a small horse. And then so I had to take that along with Klonopin, and then that – after my treatments, the only thing – those medicines would make me sleep, but that was – I wasn’t even taking them for pain. I was just taking them to sleep. But then I immediately weaned myself off of them, because I was afraid of – I’ve got to find out what the underlying issue is instead of just taking a pill to mask it.” (Male, 43 yrs, testicular)

Sleeping pills were also used by some people as a way to ‘catch up’ on lost sleep from previous nights with insomnia with the thought that it might help break the pattern of insomnia or at least so they could function for the next couple of days.

“But when I take that sleeping pill, as much as I don’t like taking it, if it works that particular night, which it usually helps, it certainly helps me fall back asleep more quickly. When I take that, it – I feel like I catch up, and I usually have like a day or two then where I really feel more like myself as far as getting things done.” (Male, 64 yrs, prostate)

Unfortunately, participants reported that use of sleeping medications were encouraged and normalized by their doctors.

“And even if I take an Ativan, which is what my oncologist encouraged me to do if I can’t fall asleep, I have – I feel hungover – or some sort of feeling the next day which makes it not worth it to me.” (Female, 52 yrs, breast)

Many participants reported an awareness of engaging in behaviors conducive with good sleep hygiene such as not having caffeine too late in the day, keeping the bedroom dark and cool, reserving the bed for sleep and sex only, abstaining from alcohol before bed, maintaining a regular sleep and wake schedule, etc., but several others did not realize the potential for these factors to impact their sleep.

“But most of the time when it was time to go to bed I’m usually out on my computer. And I put on my computer, I have a cup of tea or something like that. So it’s just a habit I guess. And so that hasn’t really gone away. I still have a cup of tea late at night. And tea – I don’t think the caffeine or whatever is in there prohibits me from getting sleep. It’s kind of soothing.” (Male, 66 yrs, prostate)

Participants reported that the inability to sleep came with its own form of anxiety, compounded by watching the clock in the middle of the night and worrying about the impact of poor sleep on their ability to function the next day.

“And also like if I wake up say at 2:00 and I see it’s now 4:00, then that makes it worse, because I know I have to wake up soon. So that makes the anxiety – I think I can’t fall asleep because then I’m becoming so anxious about not being able to wake up the next morning and being tired the following day.” (Female, 46 yrs, breast)

Discussion

This is the first study to specifically assess predisposing, precipitating, and perpetuating factors related to the development and maintenance of insomnia in cancer survivors. This information is crucial to fully understand the experience of insomnia, individualize treatment in cancer survivors, and advocate for increased access to evidence based non-pharmacological therapies for insomnia. Participants described a number of factors that they felt might predispose them to insomnia including family traits, an anxious temperament, and the inability to relax. While these may be long-standing qualities, various conventional and complementary strategies are available to reduce anxiety and promote relaxation (Greenlee et al., 2014), suggesting that this may be an area prime for prevention and/or intervention. Relaxation training is sometimes, but not always, included as a component of CBT-I (Riemann & Perlis, 2009). This suggests that the core components of CBT-I should be supplemented with relaxation training on a case-by-case basis, should this be identified as an issue.

Consistent with previous research, a majority of the participants interviewed reported that cancer had caused (precipitated), or significantly worsened their pre-existing insomnia (Kyle, Espie, & Morgan, 2010). This has important implications for hospital procedures,

management of treatment side effects, and physician-patient communication. Hospital procedures are notoriously disruptive to sleep. Despite an acceptance of sleep as an essential part of recovery from illness, patient sleep in hospital is frequently disrupted by modifiable environmental factors such as noise, light, unnecessary procedures, and insufficiently managed pain (Pilkington, 2013).

Provider-patient communication is key to optimal patient care, yet patients are rarely asked about their sleep during initial appointments. In a qualitative study with 26 individuals treated for cancer at a Canadian institution who met the DSM-IV-TR diagnostic criteria for insomnia, patients reported that they were not asked about sleep (Davidson, Feldman-Stewart, Brennenstuhl, & Ram, 2007). Some patients admitted they were reluctant to bring up their sleep concerns with their provider because they viewed sleep as less important than their cancer, or because they assumed the only treatment option provided would be medication. Patients also reported that they lacked information about how cancer and treatments might impact sleep.

Health care providers need to know about the sleep status of their patients in order to prevent and/or treat insomnia once it is identified. There is evidence that early intervention can be helpful for preventing the worsening of sleep disturbances during chemotherapy (Berger et al., 2009); however, systematic implementation of such programs is still lacking. Importantly, participants identified a number of perpetuating behavioral factors that are common targets in CBT-I. These included taking naps during the day, using back-lit electronics before bed, and poor sleep hygiene. One of the most problematic and pervasive perpetuating factors was use of sleeping medications. In a sample of 124 women with breast cancer, 52.4% of patients discussed sleep with their provider during active chemotherapy and 32.3% were prescribed sleep aids (Costantini, Ale-Ali, & Helsten, 2011). However, that number may not accurately represent the proportion of cancer patients taking sleeping medication because it focused only on oncologists' prescribing practices, and patients may be given sleep aids by other providers as well.

Considering the prevalence, significance, and potential impact of insomnia, cancer patients require information about both non-pharmacological and pharmacological treatments in order to make timely and informed treatment decisions. Cognitive Behavior Therapy for Insomnia (CBT-I) has demonstrated efficacy in cancer survivors and directly addresses factors identified herein (Garland et al., 2014). In addition to recommending routine screening for sleep-wake disturbances, guidelines put forth by the National Cancer Institute, National Comprehensive Cancer Network, and the Oncology Nursing Society, state that CBT-I has strong and consistent evidence as a first line intervention, whereas medication is only considered to be a useful short-term strategy (Berger, Matthews, & Kenkel, 2017). As such, it is important to make oncologists, health care administrators, and payers aware of the evidence for CBT-I so that it becomes more readily available to cancer survivors.

Limitations

The qualitative nature of the study allows for an exploration of the lived experience of insomnia but it also means that the researchers played an active role in analyzing and

extracting themes from the data. We took several measures to minimize potential influence of the researchers, such as consulting a senior researcher and sending the codes and extracted themes to a subsample of participants for validation. We also provided quotes for each theme to ensure our interpretation was fair and transparent. These interviews also relied on participants to recall past experiences, but the narratives are nonetheless an individual's representation of their lived experiences of insomnia. Furthermore, participants recruited for this study could represent more active help-seekers, who have greater interest toward insomnia treatments.

Conclusion

This study identified specific predisposing, precipitating, and perpetuating factors that can be used to better understand, prevent, and treat insomnia in cancer survivors. Patient and provider education is needed to change individual and organizational behaviors that contribute to the development and maintenance of insomnia and increase access to evidence-based nonpharmacological interventions.

Acknowledgments

Research reported in this article was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (CER-1403-14292). This manuscript is also supported in part by a grant from the National Institutes of Health/National Cancer Institute Cancer Center (P30 CA008748). The statements presented in this article are solely the responsibility of the author(s) and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee. Sincere thanks go to the participants, interventionists, oncologists, nurse practitioners, and clinical staff for their support of this study.

References

- American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5. Washington, DC: Author; 2013.
- Berger AM, Kuhn BR, Farr LA, Lynch JC, Agrawal S, Chamberlain J, Von Essen SG. 2009; Behavioral therapy intervention trial to improve sleep quality and cancer-related fatigue. *Psycho-Oncology*. 18 (6) :634–646. DOI: 10.1002/pon.1438 [PubMed: 19090531]
- Berger AM, Matthews EE, Kenkel AM. 2017; Management of Sleep-Wake Disturbances Comorbid With Cancer. *Oncology (Williston Park)*. 31 (8) :610–617. [PubMed: 28812302]
- Costantini C, Ale-Ali A, Helsten T. 2011; Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. *Journal of Palliative Medicine*. 14 (5) :563–566. DOI: 10.1089/jpm.2010.0465 [PubMed: 21388255]
- Curry LA, Nembhard IM, Bradley EH. 2009; Qualitative and mixed methods provide unique contributions to outcomes research. *Circulation*. 119 (10) :1442–1452. DOI: 10.1161/CIRCULATIONAHA.107.742775 [PubMed: 19289649]
- Davidson JR, Feldman-Stewart D, Brennenstuhl S, Ram S. 2007; How to provide insomnia interventions to people with cancer: Insights from patients. *Psycho-Oncology*. 16 (11) :1028–1038. DOI: 10.1002/pon.1183 [PubMed: 17352006]
- Drake CL, Roth T. 2006; Predisposition in the evolution of insomnia: Evidence, potential mechanisms, and future directions. *Sleep Medicine Clinics*. 1 :333–349.
- Garland SN, Gehrman P, Barg FK, Xie SX, Mao JJ. 2016; CHOosing options for insomnia in cancer effectively (CHOICE): Design of a patient centered comparative effectiveness trial of acupuncture and cognitive behavior therapy for insomnia. *Contemporary Clinical Trials*. 47 :349–355. DOI: 10.1016/j.cct.2016.02.010 [PubMed: 26956541]
- Garland SN, Johnson JA, Savard J, Gehrman P, Perlis M, Carlson L, Campbell T. 2014; Sleeping well with cancer: A systematic review of cognitive behavioral therapy for insomnia in cancer patients.

Neuropsychiatric Disease and Treatment. 10 :1113–1124. DOI: 10.2147/NDT.S47790 [PubMed: 24971014]

Greenlee H, Balneaves LG, Carlson LE, Cohen M, Deng G, Hershman D. ... Society for Integrative Oncology. 2014; Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. Journal of the National Cancer Institute. Monographs. 2014 (50) :346–358. DOI: 10.1093/jncimonographs/lgu041 [PubMed: 25749602]

Irwin MR. 2013; Depression and insomnia in cancer: Prevalence, risk factors, and effects on cancer outcomes. Current Psychiatry Reports. 15 (11) :40–4013-0404-1. doi: 10.1007/s11920-013-0404-1

Kyle SD, Espie CA, Morgan K. 2010; ...Not just a minor thing, it is something major, which stops you from functioning daily”: Quality of life and daytime functioning in insomnia. Behavioral Sleep Medicine. 8 (3) :123–140. DOI: 10.1080/15402002.2010.487450 [PubMed: 20582756]

Lis CG, Gupta D, Grutsch JF. 2008; The relationship between insomnia and patient satisfaction with quality of life in cancer. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 16 (3) :261–266. DOI: 10.1007/s00520-007-0314-z [PubMed: 17684773]

Perlis, M, Shaw, PJ, Cano, G, Espie, CA. Models of insomnia. In: Kryger, MH, Roth, T, Dement, WC, editors. Principles and practice of sleep medicine. 5. St. Louis, Missouri: Elsevier; 2011. 850–865.

Pilkington S. 2013; Causes and consequences of sleep deprivation in hospitalised patients. Nursing Standard (Royal College of Nursing (Great Britain): 1987). 27 (49) :35–42. DOI: 10.7748/ns2013.08.27.49.35.e7649

Riemann D, Perlis ML. 2009; The treatments of chronic insomnia: A review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Medicine Reviews. 13 (3) :205–214. DOI: 10.1016/j.smr.2008.06.001 [PubMed: 19201632]

Ruel S, Savard J, Ivers H. 2015; Insomnia and self-reported infections in cancer patients: An 18-month longitudinal study. Health Psychology: Official Journal of the Division of Health Psychology, American Psychological Association. 34 (10) :983–991. DOI: 10.1037/hea0000181

Savard J, Ivers H, Villa J, Caplette-Gingras A, Morin CM. 2011; Natural course of insomnia comorbid with cancer: An 18-month longitudinal study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 29 (26) :3580–3586. DOI: 10.1200/JCO.2010.33.2247 [PubMed: 21825267]

Spielman AJ, Caruso LS, Glovinsky PB. 1987; A behavioral perspective on insomnia treatment. The Psychiatric Clinics of North America. 10 (4) :541–553. [PubMed: 3332317]

Stepanski EJ, Walker MS, Schwartzberg LS, Blakely LJ, Ong JC, Houts AC. 2009; The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer. Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine. 5 (2) :132–136.

Appendix A

Baseline Pre Treatment Interview	
<i>We are interested in learning about your experience with insomnia and what factors, if any, have impacted your insomnia. Please try to be as descriptive as possible in your response. There is no right or wrong answers. All your answers will be audio recorded and your name will be concealed using a participant ID number, and will remain confidential. Do you have any questions? Are you ready to begin?</i>	
<i>If patient says “yes”, turn the recorder ON and state the following:</i>	
<ul style="list-style-type: none"> • Subject Database Number: Baseline#_____ • Date_____ 	
Content: Background	
1.	Tell me about your insomnia?
2.	How did your insomnia start? Can you remember when it started?

3.	What factors, if any, have influenced how severe your insomnia is? How long have you had insomnia? Did your insomnia get worse or better?
4.	In what ways, if any, has your insomnia, cancer diagnosis and or treatment affected your daily functioning?
5.	How has your insomnia impacted other important areas of your life, if at all? <i>For example, relationship with others, work flow, memory, concentration, attention, etc.?</i>
6.	What treatments or strategies have you used to try and manage your insomnia? How did they work?
7.	Is there anything else about your experience that you think is important for us to know?

Figure 1.
The 3 P Model of Insomnia

Table 1

Demographic and Clinical Characteristics

	M ± SD	
Age	60.5 ± 12.2	
	N	(%)
Gender		
Male	26	41
Female	37	59
Race		
White	44	70
Non-white	19	30
Education		
High school or less	5	8
College or above	58	92
Marital status		
Not married	29	46
Married/living with partner	34	54
Cancer type		
Breast	22	35
Prostate	13	21
Colon/Rectal	4	6
Head/Neck	2	3
Melanoma	4	6
Lymphoma	7	11
Leukemia	3	5
Lung	4	6
Other	13	21
Cancer stage		
Stage 0	1	1
Stage I	23	36
Stage II	9	14
Stage III	6	9
Stage IV	7	11
Unknown	16	25